Coxsackie adenovirus receptor expression in carcinomas of the head and neck

Anticancer Research

Volumn 32, Issue 3, 2012, Pages 1057-1062

  Wunder, Tina ^a   Schumacher, Udo ^a   Friedrich, Reinhard E ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Coxsackie adenovirus receptor (CAR); Immunohistochemistry; Nasopharyngeal carcinoma; Oncolytic therapy

Indexed keywords

COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR;

ADULT; AGED; ARTICLE; CANCER GRADING; CLINICAL ARTICLE; DISEASE ASSOCIATION; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; RECEPTORS, VIRUS;

EID: 84858785324     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005. (Pubitemid 40372904)
2. Rübe C, Grevers G, Grimminger H, Wendt T and Rohloff R: Primary radiotherapy of nasopharyngeal carcinoma. Laryngorhinootologie 74: 103-107, 1995.
3. Argiris A, Karamouzis MV, Raben D and Ferris RL: Head and neck cancer. Lancet 371: 1695-1709, 2008. (Pubitemid 351671886)
4. Seiwert TY and Cohen EE: State-of-the-art management of locally advanced head and neck cancer. Br J Cancer 92: 1341-1348, 2005. (Pubitemid 40704997)
5. Bachouchi M, Cvitkovic E, Azli N, Gasmi J, Cortes-Funes H, Boussen H, Rahal M, Kalifa C, Schwaab G, Eschwege F, Wibault P and Armand JP: High complete response in advanced nasopharyngeal carcinoma with bleomycin, epirubicin, and cisplatin before radiotherapy. J Natl Cancer Inst 82: 616-620, 1990. (Pubitemid 20115455)
6. Kirn D: Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer. Oncogene 19: 6660-6669, 2000.
7. Bergelson JM: Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275: 1320-1323, 1997.
8. Cohen CJ, Shieh JT, Picklres RJ, Okewaga T, Hsieh JT and Bergelson JM: The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction. Proc Natl Acad Sci USA 98: 15191-15196, 2001. (Pubitemid 34013991)
9. Williams AF and Barclay AN: The immunoglobulin superfamily-domains for cell surface recognition. Annu Rev Immunol 6: 381-405, 1988. (Pubitemid 19141589)
10. Natbantoglu J, Pari G, Karpati G and Holland PC: Expression of the primary coxsackie and adenovirus receptor is down regulated during skeletal muscle maturation and limits the efficacy of adenovirus mediated gene delivery to muscle cells, Hum. Gene Ther 10: 1009-1019, 1999. (Pubitemid 29195430)
11. Honda TH, Saitoh M, Masuko T, Katagiri-Abe T, Tominaga K, Kozakai I, Kobayashi K, Kumanishi T, Watanabe YG, Odani S and Kuwano R: The coxsackievirus and adenovirus receptor protein as a cell adhesion molecule in the developing mouse brain. Mol Brain Res 77: 19-28, 2000. (Pubitemid 30256188)
12. Noutsias M, Fechner H, de Jonge H, Wang X, Dekkers D, Houtsmuller AB, Pauschinger M, Bergelson J, Warraich R, Yacoub M, Hetzer R, Lamers J, Schultheiss HP and Poller W: Human coxsackie-adenovirus receptor is colocalized with integrins alpha(v)beta(3) and alpha(v)beta(5) on the cardiomyocyte sarcolemma and upregulated in dilated cardiomyopathy: implications for cardiotropic viral infections. Circulation 104: 275-280, 2001. (Pubitemid 32666947)
13. Rauen KA, Sudilovsky D, Le JL, Chew KL, Hann B, Weinberg V, Schmitt LD and Mc Cornick F: Expression of the Coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: potential relevance to gene therapy. Cancer Res 62: 3812-3818, 2002. (Pubitemid 34728866)
14. Stecker K, Vieth M, Koschel A, Wiedenmann B, Röcken C and Anders M: Impact of the coxsackievirus and adenovirus receptor on the adenoma-carcinoma sequence of colon cancer. Br J Cancer 104: 1426-1433, 2011.
15. Kim M, Zinn KR, Barnett BG, Sumerel LA, Krasnykh V, Curiel DT and Douglas JT: The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells, Eur J Cancer 38: 1917-1926, 2002. (Pubitemid 35247478)
16. Matsumoto K, Shariat SF, Ayala GE, Rauen KA and Lerner SP: Loss of Coxsackie and adenovirus receptor expression is associated with features of aggressive bladder cancer, Urology 66: 441-446, 2005. (Pubitemid 41138121)
17. Graat HC, Wuisman PI, van Beusechem VW, Crette JE, Gerritsen WR, Bras J, haap GR, Kaspers GJ, Ogose A, Gu W, Kawashima H and Hotta T: Coxsackievirus and adenovirus receptor expression on primary osteosarcoma specimens and implications for gene therapy with recombinant adenoviruses, Clin. Cancer Res 11: 2445-2447, 2005.
18. Li Y, Pong RC, Bergelson JM, Hall MC, Sagalowsky AI, Tseng CP, Wang Z and Hsieh JT: Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy, Cancer Res 59: 325-330, 1999. (Pubitemid 29048862)
19. American Joint Committee on Cancer. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer, 2002.
20. Wolff HA, Rödel RM, Gunawan B, Overbeck T, Herrmann MK, Hennies S, Hille A, Vorwerk H, Matthias C, Hess CF and Christiansen H: Nasopharyngeal carcinoma in adults: treatment results after long-term follow-up with special reference to adjuvant interferon-beta in undifferentiated carcinomas. J Cancer Res Clin Oncol 136: 89-97, 2010.
21. Gu W, Ogose A, Kawashima H, Ito M, Ito T, Matsuba A, Kitahara H, Hotta T, Tokunaga K, Hatano H, Morita T, Urakawa S, Yoshizawa T, Kawashima H, Kuwano R and Endo N: High-level expression of the coxsackievirus and adenovirus receptor messenger RNA in osteosarcoma, Ewing's sarcoma, and benign neurogenic tumors among musculoskeletal tumors. Clin Cancer Res 10: 3831-3838, 2004. (Pubitemid 38697619)
22. Marsee DK, Vadysirisack DD, Morrison CD, Prasad ML, Eng C, Duh QY, Rauen KA, Kloos RT and Jhiang SM: Variable expression of coxsackie-adenovirus receptor in thyroid tumors: implications for adenoviral gene therapy. Thyroid 15: 977-987, 2005. (Pubitemid 41475707)
23. Pan JJ, Zhang SW, Chen CB, Xiao SW, Sun Y, Liu CQ, Su X, Li DM, Xu G, Xu B and Lu YY: Effect of recombinant adenovirus-p53 combined with radiotherapy on long-term prognosis of advanced nasopharyngeal carcinoma. J Clin Oncol 27: 799-804, 2009.
24. Li D, Duan L, Freimuth P and O'Malley BW Jr: Variability of adenovirus receptor densitiy influences gene transfer efficiency and therapeutic response in head and neck cancer. Clin Cancer Res 5: 4175-4181, 1999. (Pubitemid 30013802)
25. Jee YS, Lee SG, Lee JC, Kim MJ, Lee JJ, Kim DY, Park SW, Sung MW and Heo DS: Reduced expression of coxsackie and adenovirus receptor (CAR) in tumor tissue compared to normal epithelium in head and neck squamous cell carcinoma patients. Anticancer Res 22: 2629-2634, 2002. (Pubitemid 36069290)
26. Raschperger E, Thyberg J, Pettersson S, Philipson L, Fuxe J and Pettersson RF: The coxsackie- and adenovirus receptor (CAR) is an in vivo marker for epithelial tight junctions, with a potential role in regulating permeability and tissue homeostasis. Exp Cell Res 312: 1566-1580, 2006.
27. Jojović M, Adam E, Zangemeister-Wittke U and Schumacher U: Epithelial glycoprotein-2 expression is subject to regulatory processes in epithelial-mesenchymal transitions during metastases: an investigation of human cancers transplanted into severe combined immunodeficient mice. Histochem J 30: 723-729, 1998. (Pubitemid 28551803)
28. Ganly I, Kirn D, Eckhardt G, Rodriguez GI, Soutar DS, Otto R, Robertson AG, Park O, Gulley ML, Heise C, Von Hoff DD and Kaye SB: A phase I study of Onyx-015, an ElB attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 6: 798-806, 2000. (Pubitemid 30159332)